crisaborole vs difamilast

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: PDE4 · full Atopic Dermatitis pipeline

crisaborole · Eucrisa

Marketed by Pfizer

Approved in Atopic Dermatitissmall molecule
Reliable signal

NCT02118792 · Phase 3 · completed

This was a randomized, quadruple-blind, vehicle-controlled trial with 763 participants. Its clinical primary efficacy endpoint—clear or almost clear skin with at least a two-grade improvement at Day 29—was met, with 31.4% success on crisaborole versus 18.0% on vehicle (p<0.001).

Next expected readout: January 2027 · NCT07162896 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29; Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs) (AEs: Baseline (Day 1) up to Day 29, SAEs: Baseline (Day 1) up to Day 36); Number of Participants With Clinically Significant Change From Baseline in Vital Signs at Day 29 (Baseline, Day 29); Number of Participants With Clinically Significant Change From Baseline in Laboratory Values at Day 29 (Baseline, Day 29): Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29 (Day 29): AN2728 Topical Ointment, 2 Percent 32.8% vs AN2728 Topical Ointment, Vehicle 25.4% (met)

Result source: NCT02118766

difamilast · Moizerto / Adquey

Marketed by Aurobindo Pharma and partners

Approved in Atopic Dermatitissmall molecule
Partial signal

NCT03908970 · Phase 3 · completed

This was a randomized, triple-blind (participant, investigator, and care provider), placebo-controlled Phase 3 trial in 364 adult patients with atopic dermatitis. The primary endpoint was the IGA responder rate at Week 4, which was met: 38.46% (95% CI 31.36–45.95) for 1% OPA-15406 versus 12.64% (95% CI 8.18–18.36) for placebo. The trial was adequately powered and used a validated clinical disease activity measure.

Next expected readout: December 2026 · NCT07173478 (registry estimate)

Reported efficacy

Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity (At Week 4): Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity (At Week 4): 1% OPA-15406 38.46% (95% CI 31.36 to 45.95) vs Placebo 12.64% (95% CI 8.18 to 18.36) (met)

Result source: NCT03908970

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointcrisaboroledifamilast
EASI-7546.4% vs 27.6%+18.8 vs placebo2% twice a day · wk 4.14 · n 260NCT04360187
3 other results
  • 38.2% vs 26.3% 2% twice a day · wk 3.14 · n 260 · Phase 3 · secondary NCT04360187
  • 26.3% vs 15.4% 2% twice a day · wk 2.14 · n 260 · Phase 3 · secondary NCT04360187
  • 11.2% vs 6.1% 2% twice a day · wk 1.14 · n 260 · Phase 3 · secondary NCT04360187
—Not posted · NCT05571943
IGA 0/1 with 2-point improvement—Trial running · NCT07162896—Not posted · NCT05571943
EASI-90—Trial running · NCT07162896—Not posted · NCT05571943
EASI, % change-59.9% vs -42.8%−17.1 vs placebo2% twice a day · wk 4 · n 260NCT04360187
41 other results
  • -49.8% vs -39.3% 2% QD · wk 52 · n 125 · Phase 3 · secondary NCT04040192
  • 250.1% vs -39.3% 2% BID · wk 52 · n 175 · Phase 3 · secondary NCT04040192
  • -59.9% vs -54.3% 2% QD · wk 52 · n 125 · Phase 3 · secondary NCT04040192
  • -30.0% vs -22.2% 2% QD · wk 48 · n 125 · Phase 3 · secondary NCT04040192
  • 390.3% vs -22.2% 2% BID · wk 48 · n 175 · Phase 3 · secondary NCT04040192
  • -39.1% vs -27.3% 2% QD · wk 48 · n 125 · Phase 3 · secondary NCT04040192
  • 127.6% vs -59.7% 2% QD · wk 44 · n 125 · Phase 3 · secondary NCT04040192
  • 444% vs -59.7% 2% BID · wk 44 · n 175 · Phase 3 · secondary NCT04040192
  • -12.9% vs 10% 2% QD · wk 40 · n 125 · Phase 3 · secondary NCT04040192
  • 330.8% vs 10% 2% BID · wk 40 · n 175 · Phase 3 · secondary NCT04040192
  • -47.6% vs 2.2% 2% QD · wk 40 · n 125 · Phase 3 · secondary NCT04040192
  • 211.1% vs -56.0% 2% QD · wk 36 · n 125 · Phase 3 · secondary NCT04040192
  • 184.3% vs -56.0% 2% BID · wk 36 · n 175 · Phase 3 · secondary NCT04040192
  • -19.3% vs 13.6% 2% QD · wk 32 · n 125 · Phase 3 · secondary NCT04040192
  • 341.2% vs 13.6% 2% BID · wk 32 · n 175 · Phase 3 · secondary NCT04040192
  • -27.8% vs -28.4% 2% QD · wk 32 · n 125 · Phase 3 · secondary NCT04040192
  • -33.0% vs 19.2% 2% QD · wk 28 · n 125 · Phase 3 · secondary NCT04040192
  • 454.0% vs 19.2% 2% BID · wk 28 · n 175 · Phase 3 · secondary NCT04040192
  • -34.5% vs 0% 2% QD · wk 28 · n 125 · Phase 3 · secondary NCT04040192
  • 6.9% vs -20.6% 2% QD · wk 24 · n 125 · Phase 3 · secondary NCT04040192
  • 270.2% vs -20.6% 2% BID · wk 24 · n 175 · Phase 3 · secondary NCT04040192
  • -10.8% vs -35.6% 2% QD · wk 24 · n 125 · Phase 3 · secondary NCT04040192
  • -45.4% vs 26.4% 2% QD · wk 20 · n 125 · Phase 3 · secondary NCT04040192
  • 264.7% vs 26.4% 2% BID · wk 20 · n 175 · Phase 3 · secondary NCT04040192
  • -74.3% vs 200% 2% QD · wk 20 · n 125 · Phase 3 · secondary NCT04040192
  • 28.0% vs 26.3% 2% QD · wk 16 · n 125 · Phase 3 · secondary NCT04040192
  • 272.9% vs 26.3% 2% BID · wk 16 · n 175 · Phase 3 · secondary NCT04040192
  • -0.5% vs -14.8% 2% QD · wk 16 · n 125 · Phase 3 · secondary NCT04040192
  • -8.2% vs -0.1% 2% QD · wk 12 · n 125 · Phase 3 · secondary NCT04040192
  • 401.4% vs -0.1% 2% BID · wk 12 · n 175 · Phase 3 · secondary NCT04040192
  • -9.4% vs 2.2% 2% QD · wk 12 · n 125 · Phase 3 · secondary NCT04040192
  • 34.3% vs 1.0% 2% QD · wk 8 · n 125 · Phase 3 · secondary NCT04040192
  • 239.9% vs 1.0% 2% BID · wk 8 · n 175 · Phase 3 · secondary NCT04040192
  • 10.4% vs -21.3% 2% QD · wk 8 · n 125 · Phase 3 · secondary NCT04040192
  • -59.9% vs -42.8% 2% twice a day · wk 4.14 · n 260 · Phase 3 · secondary NCT04360187
  • -10.2% vs 2.9% 2% QD · wk 4 · n 125 · Phase 3 · secondary NCT04040192
  • 407.5% vs 2.9% 2% BID · wk 4 · n 175 · Phase 3 · secondary NCT04040192
  • -10.3% vs -0.5% 2% QD · wk 4 · n 125 · Phase 3 · secondary NCT04040192
  • -55.0% vs -42.9% 2% twice a day · wk 3.14 · n 260 · Phase 3 · secondary NCT04360187
  • -49.6% vs -37.1% 2% twice a day · wk 2.14 · n 260 · Phase 3 · secondary NCT04360187
  • -36.6% vs -21.4% 2% twice a day · wk 1.14 · n 260 · Phase 3 · secondary NCT04360187
—Not posted · NCT05571943

EASI-75

crisaborole
46.4% vs 27.6%+18.8 vs placebo2% twice a day · wk 4.14 · n 260NCT04360187
3 other results
  • 38.2% vs 26.3% 2% twice a day · wk 3.14 · n 260 · Phase 3 · secondary NCT04360187
  • 26.3% vs 15.4% 2% twice a day · wk 2.14 · n 260 · Phase 3 · secondary NCT04360187
  • 11.2% vs 6.1% 2% twice a day · wk 1.14 · n 260 · Phase 3 · secondary NCT04360187
difamilast
—Not posted · NCT05571943

IGA 0/1 with 2-point improvement

crisaborole
—Trial running · NCT07162896
difamilast
—Not posted · NCT05571943

EASI-90

crisaborole
—Trial running · NCT07162896
difamilast
—Not posted · NCT05571943

EASI, % change

crisaborole
-59.9% vs -42.8%−17.1 vs placebo2% twice a day · wk 4 · n 260NCT04360187
41 other results
  • -49.8% vs -39.3% 2% QD · wk 52 · n 125 · Phase 3 · secondary NCT04040192
  • 250.1% vs -39.3% 2% BID · wk 52 · n 175 · Phase 3 · secondary NCT04040192
  • -59.9% vs -54.3% 2% QD · wk 52 · n 125 · Phase 3 · secondary NCT04040192
  • -30.0% vs -22.2% 2% QD · wk 48 · n 125 · Phase 3 · secondary NCT04040192
  • 390.3% vs -22.2% 2% BID · wk 48 · n 175 · Phase 3 · secondary NCT04040192
  • -39.1% vs -27.3% 2% QD · wk 48 · n 125 · Phase 3 · secondary NCT04040192
  • 127.6% vs -59.7% 2% QD · wk 44 · n 125 · Phase 3 · secondary NCT04040192
  • 444% vs -59.7% 2% BID · wk 44 · n 175 · Phase 3 · secondary NCT04040192
  • -12.9% vs 10% 2% QD · wk 40 · n 125 · Phase 3 · secondary NCT04040192
  • 330.8% vs 10% 2% BID · wk 40 · n 175 · Phase 3 · secondary NCT04040192
  • -47.6% vs 2.2% 2% QD · wk 40 · n 125 · Phase 3 · secondary NCT04040192
  • 211.1% vs -56.0% 2% QD · wk 36 · n 125 · Phase 3 · secondary NCT04040192
  • 184.3% vs -56.0% 2% BID · wk 36 · n 175 · Phase 3 · secondary NCT04040192
  • -19.3% vs 13.6% 2% QD · wk 32 · n 125 · Phase 3 · secondary NCT04040192
  • 341.2% vs 13.6% 2% BID · wk 32 · n 175 · Phase 3 · secondary NCT04040192
  • -27.8% vs -28.4% 2% QD · wk 32 · n 125 · Phase 3 · secondary NCT04040192
  • -33.0% vs 19.2% 2% QD · wk 28 · n 125 · Phase 3 · secondary NCT04040192
  • 454.0% vs 19.2% 2% BID · wk 28 · n 175 · Phase 3 · secondary NCT04040192
  • -34.5% vs 0% 2% QD · wk 28 · n 125 · Phase 3 · secondary NCT04040192
  • 6.9% vs -20.6% 2% QD · wk 24 · n 125 · Phase 3 · secondary NCT04040192
  • 270.2% vs -20.6% 2% BID · wk 24 · n 175 · Phase 3 · secondary NCT04040192
  • -10.8% vs -35.6% 2% QD · wk 24 · n 125 · Phase 3 · secondary NCT04040192
  • -45.4% vs 26.4% 2% QD · wk 20 · n 125 · Phase 3 · secondary NCT04040192
  • 264.7% vs 26.4% 2% BID · wk 20 · n 175 · Phase 3 · secondary NCT04040192
  • -74.3% vs 200% 2% QD · wk 20 · n 125 · Phase 3 · secondary NCT04040192
  • 28.0% vs 26.3% 2% QD · wk 16 · n 125 · Phase 3 · secondary NCT04040192
  • 272.9% vs 26.3% 2% BID · wk 16 · n 175 · Phase 3 · secondary NCT04040192
  • -0.5% vs -14.8% 2% QD · wk 16 · n 125 · Phase 3 · secondary NCT04040192
  • -8.2% vs -0.1% 2% QD · wk 12 · n 125 · Phase 3 · secondary NCT04040192
  • 401.4% vs -0.1% 2% BID · wk 12 · n 175 · Phase 3 · secondary NCT04040192
  • -9.4% vs 2.2% 2% QD · wk 12 · n 125 · Phase 3 · secondary NCT04040192
  • 34.3% vs 1.0% 2% QD · wk 8 · n 125 · Phase 3 · secondary NCT04040192
  • 239.9% vs 1.0% 2% BID · wk 8 · n 175 · Phase 3 · secondary NCT04040192
  • 10.4% vs -21.3% 2% QD · wk 8 · n 125 · Phase 3 · secondary NCT04040192
  • -59.9% vs -42.8% 2% twice a day · wk 4.14 · n 260 · Phase 3 · secondary NCT04360187
  • -10.2% vs 2.9% 2% QD · wk 4 · n 125 · Phase 3 · secondary NCT04040192
  • 407.5% vs 2.9% 2% BID · wk 4 · n 175 · Phase 3 · secondary NCT04040192
  • -10.3% vs -0.5% 2% QD · wk 4 · n 125 · Phase 3 · secondary NCT04040192
  • -55.0% vs -42.9% 2% twice a day · wk 3.14 · n 260 · Phase 3 · secondary NCT04360187
  • -49.6% vs -37.1% 2% twice a day · wk 2.14 · n 260 · Phase 3 · secondary NCT04360187
  • -36.6% vs -21.4% 2% twice a day · wk 1.14 · n 260 · Phase 3 · secondary NCT04360187
difamilast
—Not posted · NCT05571943
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. crisaborole: 7 of 7 rows · difamilast: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriccrisaborole
Rows use multiple source trials
difamilast
Rows use multiple source trials
BSA
absolute change · percentage points
6.25% (n=175) vs 1.16% (n=129) placebo @ 4wk2% BIDa,b,c,d
NCT04040192 · Phase 3 · registry result, not featured evidence
show 3 more doses
0.52% (n=125) vs 1.16% (n=129) placebo @ 4wk2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
0.53% (n=125) vs 1.2% (n=129) placebo @ 4wk2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
4.17% (n=81) vs 6.92% (n=96) placebo @ 4wk2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
-3.94% (n=57) vs -0.32% (n=53) placebo @ 4wk0.3%a,b,c,d
NCT02914548 · Phase 2 · registry result, not featured evidence
show 1 more dose
-3.73% (n=58) vs -0.32% (n=53) placebo @ 4wk1%
NCT02914548 · Phase 2 · registry result, not featured evidence
IGA
absolute change · score
-1.9 vs -1 placebo score @ 2.14wk2% BIDa,c,d,e
NCT03954158 · Phase 2 · registry result, not featured evidence
show 3 more doses
-1.9 vs -1 placebo score @ 2.14wk2% BID
NCT03954158 · Phase 2 · registry result, not featured evidence
-1.9 vs -1 placebo score @ 2.14wk2% QD
NCT03954158 · Phase 2 · registry result, not featured evidence
-1.8 vs -1 placebo score @ 2.14wk2% QD
NCT03954158 · Phase 2 · registry result, not featured evidence
-0.56 vs -0.09 placebo score @ 4wk0.3%a,c,d,e
NCT02068352 · Phase 2
show 3 more doses
-0.54 vs -0.04 placebo score @ 4wk0.3%
NCT02068352 · Phase 2
-0.55 vs -0.09 placebo score @ 4wk1%
NCT02068352 · Phase 2
-0.54 vs -0.04 placebo score @ 4wk1%
NCT02068352 · Phase 2
POEM
absolute change · score
-5.7 vs -3.3 placebo score @ 4.14wk2% twice a daya,b,c,d,f
NCT04360187 · Phase 3 · registry result, not featured evidence
show 1 more dose
-7.7 vs -3.8 placebo score @ 4.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
-1.36 vs -0.02 placebo score @ 4wk0.3%a,b,c,d,f
NCT02914548 · Phase 2 · registry result, not featured evidence
show 1 more dose
-2.9 vs -0.02 placebo score @ 4wk1%
NCT02914548 · Phase 2 · registry result, not featured evidence
Dropout rate
6%2% ointmentg
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 22 more results
—2% ointment
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
5.9%2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
—2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
50%
NCT03832010 · Phase 4 · registry result, not featured evidence
3.6%2%
NCT03356977 · Phase 4 · registry result, not featured evidence
—2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
—2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
—2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
—2% BID
NCT04040192 · Phase 3 · registry result, not featured evidence
5.8%2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
0%2% QD
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
0%2% BID
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
0%2% BID
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
0%2% QD
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
—
NCT03233529 · Phase 2 · registry result, not featured evidence
0%0.5% + 2% once daily
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
2.4%0.5% + 2% twice daily
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
12%2%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
4.8%1%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
4.3%2 percent
NCT01652885 · Phase 1/2 · registry result, not featured evidence
0%Cohort 1: Crisaborole Ointment 2%
NCT03260595 · Phase 1 · registry result, not featured evidence
0%Cohort 2: Crisaborole Ointment 2%
NCT03260595 · Phase 1 · registry result, not featured evidence
9.3%1%h
NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 19 more results
8.4%0.3%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
10.6%1%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
24.4%0.3%
NCT02068352 · Phase 2
18.6%1%
NCT02068352 · Phase 2
8.3%0.3%
NCT05372653 · Phase 3 · registry result, not featured evidence
13.8%1%
NCT05372653 · Phase 3 · registry result, not featured evidence
25.3%1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
11.8%0.3% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
8.9%1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
31.3%0.3%
NCT02914548 · Phase 2 · registry result, not featured evidence
20.9%1%
NCT02914548 · Phase 2 · registry result, not featured evidence
8.3%0.3%
NCT03018691 · Phase 2 · registry result, not featured evidence
4%1%
NCT03018691 · Phase 2 · registry result, not featured evidence
—0.3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—0.3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—1% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—1% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
1%2% ointmentg
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 22 more results
—2% ointment
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
1.4%2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
—2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
—
NCT03832010 · Phase 4 · registry result, not featured evidence
—2%
NCT03356977 · Phase 4 · registry result, not featured evidence
—2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
—2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
—2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
—2% BID
NCT04040192 · Phase 3 · registry result, not featured evidence
4.2%2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
—2% QD
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
—2% BID
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
—2% BID
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
—2% QD
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
—
NCT03233529 · Phase 2 · registry result, not featured evidence
0%0.5% + 2% once daily
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
2.4%0.5% + 2% twice daily
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
—2%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
—1%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
4.3%2 percent
NCT01652885 · Phase 1/2 · registry result, not featured evidence
—Cohort 1: Crisaborole Ointment 2%
NCT03260595 · Phase 1 · registry result, not featured evidence
—Cohort 2: Crisaborole Ointment 2%
NCT03260595 · Phase 1 · registry result, not featured evidence
3.8%1%h
NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 19 more results
1.2%0.3%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.4%1%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
9.8%0.3%
NCT02068352 · Phase 2
4.7%1%
NCT02068352 · Phase 2
0%0.3%
NCT05372653 · Phase 3 · registry result, not featured evidence
3.4%1%
NCT05372653 · Phase 3 · registry result, not featured evidence
7.8%1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
3.5%0.3% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
3.6%1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
22.4%0.3%
NCT02914548 · Phase 2 · registry result, not featured evidence
10.4%1%
NCT02914548 · Phase 2 · registry result, not featured evidence
4.2%0.3%
NCT03018691 · Phase 2 · registry result, not featured evidence
4%1%
NCT03018691 · Phase 2 · registry result, not featured evidence
—0.3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—0.3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—1% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—1% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
Serious AEs
—2% ointmentg
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 22 more results
0.6%2% ointment
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
—2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
1%2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
0%
NCT03832010 · Phase 4 · registry result, not featured evidence
0.7%2%
NCT03356977 · Phase 4 · registry result, not featured evidence
—2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
1.3%2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
1.5%2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
0.6%2% BID
NCT04040192 · Phase 3 · registry result, not featured evidence
0.4%2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
0%2% QD
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
0%2% BID
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
0%2% BID
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
0%2% QD
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
0%
NCT03233529 · Phase 2 · registry result, not featured evidence
0%0.5% + 2% once daily
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
0%0.5% + 2% twice daily
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
0%2%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
0%1%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
0%2 percent
NCT01652885 · Phase 1/2 · registry result, not featured evidence
0%Cohort 1: Crisaborole Ointment 2%
NCT03260595 · Phase 1 · registry result, not featured evidence
0%Cohort 2: Crisaborole Ointment 2%
NCT03260595 · Phase 1 · registry result, not featured evidence
0%1%h
NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 19 more results
0%0.3%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%1%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4.9%0.3%
NCT02068352 · Phase 2
4.7%1%
NCT02068352 · Phase 2
2.4%0.3%
NCT05372653 · Phase 3 · registry result, not featured evidence
3.4%1%
NCT05372653 · Phase 3 · registry result, not featured evidence
1.2%1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
0.7%0.3% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
0%1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
0%0.3%
NCT02914548 · Phase 2 · registry result, not featured evidence
0%1%
NCT02914548 · Phase 2 · registry result, not featured evidence
0%0.3%
NCT03018691 · Phase 2 · registry result, not featured evidence
0%1%
NCT03018691 · Phase 2 · registry result, not featured evidence
0%0.3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
0%0.3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
0%1% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
0%1% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
0%3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
0%3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
2% ointmentg
upper respiratory tract infection 3.1% (placebo 2%)
application site pain 2.7% (placebo 1.2%)
nasopharyngitis 1.8% (placebo 2.4%)
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 19 more results
2%
burning/stinging: mild 23.9% (placebo 19%)
burning/stinging: moderate 18.1% (placebo 17.1%)
burning/stinging: severe 8.2% (placebo 4%)
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
burning sensation after the first application of the assigned study medication. 12.5% (placebo 0%)
NCT03832010 · Phase 4 · registry result, not featured evidence
2%
pyrexia 9.5%
diarrhoea 7.3%
upper respiratory tract infection 7.3%
NCT03356977 · Phase 4 · registry result, not featured evidence
2% QD
dermatitis atopic 2.6% (placebo 2.2%)
application site acne 1.3% (placebo 0%)
application site infection 1.3% (placebo 3.4%)
NCT04040192 · Phase 3 · registry result, not featured evidence
2% QD
covid-19 3.7% (placebo 1.1%)
upper respiratory tract infection 3% (placebo 1.1%)
headache 2.2% (placebo 1.1%)
NCT04040192 · Phase 3 · registry result, not featured evidence
2% BID
application site pain 5.6% (placebo 1.1%)
dermatitis atopic 2.4% (placebo 2.2%)
upper respiratory tract infection 2% (placebo 1.1%)
NCT04040192 · Phase 3 · registry result, not featured evidence
2% twice a day
application site pain 13.1% (placebo 3.8%)
dermatitis atopic 7.7% (placebo 11.5%)
application site discolouration 3.5% (placebo 0.8%)
NCT04360187 · Phase 3 · registry result, not featured evidence
2% QD
application site irritation 15%
application site pruritus 15%
application site folliculitis 5%
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
2% BID
application site irritation 19%
oropharyngeal pain 14.3%
application site pruritus 9.5%
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
2% BID
application site pain 5%
application site pruritus 5%
hand-foot-and-mouth disease 5%
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
2% QD
arthralgia 5%
hand-foot-and-mouth disease 5%
application site coldness 0%
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
dermatitis atopic 12.8%
nasopharyngitis 12.8%
application site pain 10.3%
NCT03233529 · Phase 2 · registry result, not featured evidence
0.5% + 2% once daily
application site pain 4.5%
application site pruritus 2.3%
asthma 2.3%
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
0.5% + 2% twice daily
nasopharyngitis 4.8%
application site pruritus 2.4%
arthralgia 2.4%
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
2%
upper respiratory tract infection 24%
headache 8%
application site erythema 4%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
1%
upper respiratory tract infection 14.3%
application site cellulitis 4.8%
application site erythema 4.8%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
2 percent
application site pain 13%
nasopharyngitis 13%
dysmenorrhoea 5.3%
NCT01652885 · Phase 1/2 · registry result, not featured evidence
application site coldness 0% (placebo 50%)
application site irritation 0% (placebo 50%)
application site pain 0% (placebo 50%)
NCT03260595 · Phase 1 · registry result, not featured evidence
application site irritation 70% (placebo 50%)
application site pain 40% (placebo 50%)
application site coldness 10% (placebo 50%)
NCT03260595 · Phase 1 · registry result, not featured evidence
1%h
dermatitis atopic 3.8% (placebo 12.1%)
NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 13 more results
0.3%
impetigo 7.2% (placebo 6%)
nasopharyngitis 6% (placebo 3.6%)
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1%
nasopharyngitis 8.2% (placebo 3.6%)
impetigo 2.4% (placebo 6%)
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.3%
dermatitis atopic 26.8% (placebo 21.6%)
nasopharyngitis 7.3% (placebo 8.1%)
pruritus 7.3% (placebo 2.7%)
NCT02068352 · Phase 2
1%
dermatitis atopic 16.3% (placebo 21.6%)
headache 7% (placebo 0%)
nasopharyngitis 2.3% (placebo 8.1%)
NCT02068352 · Phase 2
0.3%
nasopharyngitis 43.9%
dermatitis contact 19.5%
miliaria 12.2%
NCT05372653 · Phase 3 · registry result, not featured evidence
1%
nasopharyngitis 82.8%
gastroenteritis 55.2%
dermatitis diaper 34.5%
NCT05372653 · Phase 3 · registry result, not featured evidence
1% ointment
dermatitis atopic 21.1%
nasopharyngitis 14.5%
folliculitis 6%
NCT03961529 · Phase 3 · registry result, not featured evidence
0.3% ointment
nasopharyngitis 32.6%
dermatitis atopic 20.8%
impetigo 18.1%
NCT03961529 · Phase 3 · registry result, not featured evidence
1% ointment
dermatitis atopic 30.4%
nasopharyngitis 30.4%
conjunctivitis allergic 12.5%
NCT03961529 · Phase 3 · registry result, not featured evidence
0.3%
dermatitis atopic 16.4% (placebo 18.2%)
viral upper respiratory tract infection 10.4% (placebo 10.6%)
pruritus 7.5% (placebo 6.1%)
NCT02914548 · Phase 2 · registry result, not featured evidence
1%
dermatitis atopic 9% (placebo 18.2%)
viral upper respiratory tract infection 6% (placebo 10.6%)
pruritus 1.5% (placebo 6.1%)
NCT02914548 · Phase 2 · registry result, not featured evidence
0.3%
dermatitis atopic 8.3% (placebo 16.7%)
influenza 8.3% (placebo 0%)
upper respiratory tract inflammation 4.2% (placebo 8.3%)
NCT03018691 · Phase 2 · registry result, not featured evidence
1%
upper respiratory tract inflammation 24% (placebo 8.3%)
blood alkaline phosphatase increased 8% (placebo 0%)
dermatitis atopic 4% (placebo 16.7%)
NCT03018691 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 2.14 weeks versus 4 weeks.
  6. fAssessment timepoints differ: 4.14 weeks versus 4 weeks.
  7. gPopulation comparability has not been reviewed for 19 of these studies.
  8. hPopulation comparability has not been reviewed for 17 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

crisaborole

ISGA Success 31.4% (n=513) vs 18% (n=250) placebo @ 4wk2% ointment
responder rate · % of participants
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 6 more results
32.8% (n=503) vs 25.4% (n=256) placebo @ 4.14wk2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
27.6% (n=260) vs 15.9% (n=131) placebo @ 4wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
4.8% (n=260) vs 0% (n=131) placebo @ 1.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
11.6% (n=260) vs 4.9% (n=131) placebo @ 2.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
18.1% (n=260) vs 10.8% (n=131) placebo @ 3.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
27.6% (n=260) vs 15.9% (n=131) placebo @ 4.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
ISGA 0/1 48.5% (n=513) vs 29.7% (n=250) placebo @ 4wk2% ointment
responder rate · % of participants
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 6 more results
51.7% (n=503) vs 40.6% (n=256) placebo @ 4.14wk2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
41.4% (n=260) vs 28.5% (n=131) placebo @ 4wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
16.8% (n=260) vs 7.8% (n=131) placebo @ 1.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
25.6% (n=260) vs 18.3% (n=131) placebo @ 2.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
32.3% (n=260) vs 25.1% (n=131) placebo @ 3.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
41.4% (n=260) vs 28.5% (n=131) placebo @ 4.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
Time to ISGA Success Median NA vs NA placebo months2% ointment
time to event · months
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 1 more result
NA vs NA placebo months2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
Erythema -0.7 vs -0.3 placebo score @ 4wk2% ointment
absolute change · score
Erythema: Change at Day 29 (n =486, 224)
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
Time to Pruritus Improvement Median 0.05 vs 0.05 placebo months2% ointment
time to event · months
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3 · converted to months from 1.41 days as posted
show 1 more result
0.04 vs 0.06 placebo months*2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3 · converted to months from 1.32 days as posted
CDLQI -4 vs -2.9 placebo score @ 4.14wk2% ointment
absolute change · score
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 4 more results
5 vs 3.17 placebo score @ 4.2857wk
NCT03832010 · Phase 4 · registry result, not featured evidence
5.75 vs 2 placebo score @ 12.8571wk
NCT03832010 · Phase 4 · registry result, not featured evidence
-3.6 vs -1.3 placebo score @ 2.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
-3.9 vs -1.8 placebo score @ 4.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
DLQI -5 vs -3.4 placebo score @ 4.14wk2% ointment
absolute change · score
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 3 more results
-5.5 vs -3.6 placebo score @ 4.14wk2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
-1.7 vs -1.1 placebo score @ 2.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
-1.8 vs -1.5 placebo score @ 4.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
DFI -3.6 vs -2.8 placebo score @ 4.14wk2% ointment
absolute change · score
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 4 more results
7 vs 5.5 placebo score @ 4.2857wk
NCT03832010 · Phase 4 · registry result, not featured evidence
10.25 vs 2.6 placebo score @ 12.8571wk
NCT03832010 · Phase 4 · registry result, not featured evidence
-2.4 vs -0.5 placebo score @ 2.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
-3 vs -2.1 placebo score @ 4.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
Erythema -0.7 vs -0.4 placebo score @ 4wk2%
absolute change · score
Erythema: Change at Day 29 (n=478,228)
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
SCORAD 26.88 vs 25.4 placebo score @ 4.2857wk
absolute change · score
NCT03832010 · Phase 4 · registry result, not featured evidence
show 1 more result
25.78 vs 17.2 placebo score @ 12.8571wk
NCT03832010 · Phase 4 · registry result, not featured evidence
Pruritus 5.2 vs 4.17 placebo score @ 4.2857wk
absolute change · score
NCT03832010 · Phase 4 · registry result, not featured evidence
show 15 more results
4 vs 2.8 placebo score @ 12.8571wk
NCT03832010 · Phase 4 · registry result, not featured evidence
-1.9 vs -1 placebo score @ 0.29wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-2.2 vs -0.9 placebo score @ 0.43wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-2.4 vs -1.1 placebo score @ 0.57wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-2.7 vs -1.1 placebo score @ 0.71wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-2.6 vs -1.3 placebo score @ 0.86wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.1 vs -1.5 placebo score @ 1wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.4 vs -1.5 placebo score @ 1.14wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.4 vs -1.5 placebo score @ 1.29wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.5 vs -1.6 placebo score @ 1.43wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.5 vs -2 placebo score @ 1.57wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.7 vs -1.5 placebo score @ 1.71wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-4 vs -2.2 placebo score @ 1.86wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.9 vs -2.2 placebo score @ 2wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.9 vs -2 placebo score @ 2.14wk
NCT03233529 · Phase 2 · registry result, not featured evidence
Time to Flare 3.65 vs 0.99 placebo months @ 52wk2% QD
time to event · months
NCT04040192 · Phase 3 · registry result, not featured evidence · converted to months from 111 days as posted

+ 32 further endpoints in the CSV export.

difamilast

IGA 0/1 38.46% (n=182) vs 12.64% (n=182) placebo @ 4wk1%
responder rate · % of participants
NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 4 more results
14.93% (n=67) vs 9.09% (n=66) placebo @ 4wk0.3%
NCT02914548 · Phase 2 · registry result, not featured evidence
22.39% (n=67) vs 9.09% (n=66) placebo @ 4wk1%
NCT02914548 · Phase 2 · registry result, not featured evidence
37.5% (n=24) vs 8.33% (n=24) placebo @ 4wk0.3%
NCT03018691 · Phase 2 · registry result, not featured evidence
40% (n=25) vs 8.33% (n=24) placebo @ 4wk1%
NCT03018691 · Phase 2 · registry result, not featured evidence
EASI -4.17 vs -0.08 placebo score @ 4wk1%
absolute change · score
NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 14 more results
-4.97 vs 0.35 placebo score @ 4wk0.3%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.07 vs 0.35 placebo score @ 4wk1%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.21 vs -1.1 placebo score @ 4wk0.3%
NCT02068352 · Phase 2
-3.19 vs -1.1 placebo score @ 4wk1%
NCT02068352 · Phase 2
-2.6 vs -1.57 placebo score @ 8wk0.3%
NCT02068352 · Phase 2
-3.47 vs -1.57 placebo score @ 8wk1%
NCT02068352 · Phase 2
-2 vs -0.51 placebo score @ 4wk0.3%
NCT02068352 · Phase 2
-3.07 vs -0.51 placebo score @ 4wk1%
NCT02068352 · Phase 2
-2.42 vs -1 placebo score @ 8wk0.3%
NCT02068352 · Phase 2
-3.36 vs -1 placebo score @ 8wk1%
NCT02068352 · Phase 2
-2.32 vs -0.15 placebo score @ 4wk0.3%
NCT02914548 · Phase 2 · registry result, not featured evidence
-3.16 vs -0.15 placebo score @ 4wk1%
NCT02914548 · Phase 2 · registry result, not featured evidence
-5.33 vs 0.56 placebo score @ 4wk0.3%
NCT03018691 · Phase 2 · registry result, not featured evidence
-5.52 vs 0.56 placebo score @ 4wk1%
NCT03018691 · Phase 2 · registry result, not featured evidence
Pruritus VRS -0.65 vs -0.04 placebo score @ 4wk1%
absolute change · score
NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 6 more results
-0.8 vs -0.33 placebo score @ 4wk0.3%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.68 vs -0.33 placebo score @ 4wk1%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.43 vs -0.06 placebo score @ 0.9285714285714286wk0.3%
NCT02914548 · Phase 2 · registry result, not featured evidence
-0.49 vs -0.06 placebo score @ 0.9285714285714286wk1%
NCT02914548 · Phase 2 · registry result, not featured evidence
-0.83 vs 0.3 placebo score @ 0.93wk0.3%
NCT03018691 · Phase 2 · registry result, not featured evidence
-0.73 vs 0.3 placebo score @ 0.93wk1%
NCT03018691 · Phase 2 · registry result, not featured evidence
IGA 44.58% (n=83) vs 18.07% (n=83) placebo @ 4wk0.3%
responder rate · % of participants
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more result
47.06% (n=85) vs 18.07% (n=83) placebo @ 4wk1%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
IGA "Treatment Success 14.63% (n=41) vs 2.7% (n=37) placebo @ 4wk0.3%
responder rate · % of participants
Non-responders
NCT02068352 · Phase 2
show 3 more results
20.93% (n=43) vs 2.7% (n=37) placebo @ 4wk1%
Non-responders
NCT02068352 · Phase 2
17.07% (n=41) vs 10.81% (n=37) placebo @ 8wk0.3%
Non-responders
NCT02068352 · Phase 2
16.28% (n=43) vs 10.81% (n=37) placebo @ 8wk1%
Non-responders
NCT02068352 · Phase 2
Pruritus VAS -6.27 vs -4.87 placebo score @ 4wk0.3%
absolute change · score
NCT02068352 · Phase 2
show 7 more results
-16.71 vs -4.87 placebo score @ 4wk1%
NCT02068352 · Phase 2
-10.98 vs -7.3 placebo score @ 8wk0.3%
NCT02068352 · Phase 2
-20.71 vs -7.3 placebo score @ 8wk1%
NCT02068352 · Phase 2
-4.05 vs -3.05 placebo score @ 4wk0.3%
NCT02068352 · Phase 2
-14.59 vs -3.05 placebo score @ 4wk1%
NCT02068352 · Phase 2
-10.01 vs -7.28 placebo score @ 8wk0.3%
NCT02068352 · Phase 2
-20.33 vs -7.28 placebo score @ 8wk1%
NCT02068352 · Phase 2
IGA 0 1 2pt Improvement 56.1% (n=41) @ 4wk0.3%
responder rate · % of participants
No placebo or comparator arm
NCT05372653 · Phase 3 · registry result, not featured evidence
EASI-75 82.93% (n=41) @ 4wk0.3%
responder rate · % of participants
No placebo or comparator arm
NCT05372653 · Phase 3 · registry result, not featured evidence
show 3 more results
55.42% (n=166) @ 52wk1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
77.08% (n=144) @ 52wk0.3% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
64.29% (n=56) @ 52wk1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
IGA 0/1 34.94% (n=166) @ 52wk1% ointment
responder rate · % of participants
No placebo or comparator arm
NCT03961529 · Phase 3 · registry result, not featured evidence
show 2 more results
52.78% (n=144) @ 52wk0.3% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
51.79% (n=56) @ 52wk1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
Pruritus VAS -6.76 vs 0.9 placebo mm @ 4wk0.3%
absolute change · mm
NCT02914548 · Phase 2 · registry result, not featured evidence
show 3 more results
-6.28 vs 0.9 placebo mm @ 4wk1%
NCT02914548 · Phase 2 · registry result, not featured evidence
-18 vs 8.19 placebo mm @ 4wk0.3%
NCT03018691 · Phase 2 · registry result, not featured evidence
-17.21 vs 8.19 placebo mm @ 4wk1%
NCT03018691 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: crisaborole's landscape · difamilast's landscape